One of the HARMONY Alliance goals is to increase consistency in future studies, allowing for the results to be compared and combined. Therefore, HARMONY researchers are developing Core Outcome Sets (COS) for blood cancers. On 4 and 18 March 2022, two hackathons will be organized to develop COS for Chronic Myeloid Leukemia, Myeloproliferative Neoplasms, Hodgkin's Lymphoma, and Waldenström Macroglobulinemia.
Survey round 1 | 4 March 2022 | by Zoom | from 13:00 to approx 14:30 hrs.
Survey round 2 | 18 March 2022 | by Zoom | from 13:00 to approx 14:30 hrs.
We need your help to improve blood cancer research. Patients, clinicians, regulators and drug developers are invited to participate.
Click here to read more, download explanatory flyers and how to register >
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
